can tirzepatide cause high blood pressure Take Control of Your Weight With Call to action for drug

The rapid adoption of GLP-1 therapies is being fueled by: Clinical need: Patients with metabolic disorders are seeking therapies that offer both glycemic control and weight reduction Consumer behavior shift: Increasing acceptance of pharmacological weight-loss interventions, particularly in urban markets Physician adoption: Specialists are prescribing these drugs based on strong global clinical evidence This demand is reflected in the strong commercial performance of newer therapies

Human evidence - Phase 2 type 2 diabetes (Rosenstock et al., Lancet 2023) Adults with type 2 diabetes, 36 weeks

However, it is becoming increasingly important to understand the consequences of Ozempic when used off-label

and Verma, S

Flat-Rate Subscription Pricing Many platforms increase prices as patients move to higher therapeutic doses